Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Epirus Biopharmaceuticals Company Profile (NASDAQ:EPRS)

Consensus Ratings for Epirus Biopharmaceuticals (NASDAQ:EPRS) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $13.67 (153.56% upside)

Analysts' Ratings History for Epirus Biopharmaceuticals (NASDAQ:EPRS)
Show:
DateFirmActionRatingPrice TargetActions
5/26/2015BTIG ResearchInitiated CoverageBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/25/2015Leerink SwannBoost Price TargetOutperform$10.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/18/2015WedbushInitiated CoverageBuy$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/6/2014Leerink SwannInitiated CoverageOutperform$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/12/2013WedbushDowngradeOutperform -> Neutral$1.20View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/11/2013OppenheimerDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/30/2013 forward)